-
EOFlow Officially Launches iOS Version of the EOPatch App ‘Narsha’
▶ iOS version of the world’s first app for controlling wearable insulin pump ▶ Improved ease of use by replacing a portable controller with a smartphone app EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, today announces that it officially launches iOS Version of ‘Narsha,’ a smartphone application for wearable insulin pump in Korea. It has been nine months since the Company officially launched the Android application of Narsha. Narsha is the world’s first...May. 17. 2022 -
EOFlow Announces Record Revenue for First Quarter 2022; Revenue of 949 Million KRW which is 137% of Last Year’s Annual Revenue
▶ Highest-ever quarterly revenue! Strong revenue growth from European sales; Menarini will progressively launch the product in Europe from 2Q22 onwards! ▶ EOFlow expects significant growth in revenue in 2022 from market launches in Europe, Indonesia, and the Middle East EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, announced its Q1 financial results ended on March 31, 2022. EOFlow announced its consolidated financial results: first quarter of 2022 revenue of 949 million Korean...May. 16. 2022 -
EOFlow Has its First Clinical Study on EOPatch Published in Diabetes & Metabolism Journal
▶ A 4-Week, Two-Center, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of EOPatch in Well-Controlled Type 1 Diabetes Mellitus ▶ 4-week treatment with EOPatch was safe and led to clinically meaningful improvement in glycemic control compared to those with MDI or conventional insulin pump EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced today that its first clinical study results on the wearable insulin pump EOPatch in patients with type 1 diabetes were publ...Apr. 11. 2022 -
EOFlow to Supply KRW48.8bn Worth of EOPatch to Gulf Drug of UAE
▶ A Major Export Deal for EOFlow’s Innovative Insulin Pump EOPatch EOFlow Co. Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, has announced on March 31 that it has signed a contract with GulfDrug LLC (Gulf Drug) of the United Arab Emirates (UAE) to supply 48.8 billion Korean won (40 million US dollar) worth of EOPatch, a disposable and wearable insulin pump, over the course of five years. The Company said the contract amount is equivalent to 7043 percent (%) of its entire sales last year. T...Apr. 04. 2022 -
EOFlow Celebrates its 10th Anniversary… Commits to Move Forward with a Goal Toward Becoming a “World’s Leading Medical Device Company”
▶ EOFlow held a virtual event to celebrate its 10th anniversary ▶ Aims to become a world’s leading wearable drug delivery solution provider EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, celebrates its 10th anniversary today. In marking the 10th anniversary, CEO Jesse Kim expresses ambition for EOFlow to become a global digital healthcare company. EOFlow, founded on September 27th of 2011, launched Korea’s first (and the world’s second) tubeless, wearable, and...Sep. 27. 2021 -
EOFlow Makes a Significant Investment in EOPump Manufacturing Capacity
▶ Funding up to 18 billion KRW secured through loans from the Korea Development Bank ▶ Automation to reduce production costs and expand manufacturing capacity EOFlow (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, today announced that it will make a large investment to its EOPump manufacturing facility. EOFlow is investing in the manufacturing facility expansion and addition of automated manufacturing lines. For this purpose, the Company has recently secured a credit line of 18 billion Korean W...Sep. 06. 2021 -
EOFlow Officially Launches EOPatch’s Smartphone Application ‘Narsha’
▶ World’s first smartphone app for controlling wearable insulin pump ▶ Improved ease of use by replacing a portable device with a smartphone app ▶ EOPatch Online Education Center is now open to educate and promote benefits of wireless insulin management system EOFlow Co., Ltd. (KOSDAQ: 294090) (EOFlow or the Company), a provider of wearable drug delivery solutions, today announces that it officially launches ‘Narsha,’ a smartphone application for wearable insulin pump in Korea. Narsha is world’s first smartphone applic...Aug. 30. 2021 -
EOFlow Signs Mutual Equity Investment Agreement with UXN for Future Competitiveness
▶ EOFlow and UXN sign mutual equity investment agreement to strengthen mutual trust for future competitiveness ▶ Convergence of low-power electroosmotic pump with continuous blood glucose measurement technology for the development of two-part and integrated wearable artificial pancreas systems EOFlow(KOSDAQ, 294090), a company specializing in wearable drug delivery solutions, announced on July 30th that it will participate in the three-way allocation paid-in capital increase of UXN(KONEX, 337840). EOFlow will invest 4 billion Korean won and ac...Aug. 02. 2021 -
[Medical Observer] New Insulin and Insulin Delivery Devices the Paradigm Shift
Reporter Park from Medical Observer introduced EOFlow's wearable, disposable insulin pump EOPatch in the article today. (In Korean only: http://www.monews.co.kr/news/articleView.html?idxno=305824) At the bottom of the article, reporter Park introduced EOFlow as a company that successfully commercialized the disposable, wearable insulin pump called "EOPatch." Unlike other conventional insulin pumps, EOPatch is a small and light wearable pump without infusion lines, so it can be attached to any body areas such as the...Jul. 30. 2021 -
[Medical Observer] EOFlow develops innovative medical device for diabetes
Medical Observer released a CEO interview article today (In Korean only: http://www.monews.co.kr/news/articleView.html?idxno=305828) During the interview, EOFlow's founding CEO Jesse Kim focused on the wearable insulin pump "EOPatch" and its future product portfolio. The reporter also focused on the medical industry's views on insulin pumps. Please refer to the article for more information.Jul. 30. 2021 -
[SK Securities] Sales expected to increase in 2022
SK Securities published a company analysis report on EOFlow today on 22/07/2021. Analyst Lee commented that EOFlow's wearable disposable insulin pump was sold in Korea from 1Q21 and with national healthcare insurance, sales in EOFlow is expected to increase greatly. He also commented that the Company acquired European CE mark and plan to launch the product in Europe in 3Q21. He mentioned that the Company is also considering a partnership to establish a JV in China. Attached is a report titled "Expecting sales incre...Jul. 22. 2021 -
[MoneyToday] CEO interview on Pharmeo
MoneyToday released a CEO interview article on the newspaper and online yesterday (In Korean only: https://news.mt.co.kr/mtview.php?no=2021072014373786320, https://news.mt.co.kr/mtview.php?no=2021072014461679862) Reporter Kim focused on EOFlow's newly established pharmaceutical subsidiary 'Pharmeo'. EOFlow's CEO Jesse Kim expected the drug delivery business as a momentum to exceed global competitors. Jesse also explained the other subsidiary 'Nephria Bio' which develops wearable artificial kidneys.Jul. 20. 2021 -
[Hankyung BIO Insight] EOFlow plans to discover and develop various non-insulin drugs to expand on its wearable drug delivery business
EOFlow's establisiment of a wearable pharmaceutical subsidiary 'Pharmeo' to expand on its wearable drug delivery business was introduced on Hankyung BIO Insight on 07/12/2021 (in Korean only): https://www.hankyung.com/it/article/2021071123361 In summary, reporter Ju-Hyun Lee from Bio & Healthcare department in the Korea Economic Daily announced that EOFlow plans to discover and develop various non-insulin drugs to expand on its wearable drug delivery business through its newly established subsidiary 'Pharmeo Inc&#...Jul. 12. 2021 -
EOFlow establishes a wearable pharmaceutical subsidiary 'Pharmeo Inc.' to expand on its wearable drug delivery business
▶ Leveraging the advantages of EOFlow’s smart wearable drug delivery platform to establish a unique drug-device combination pharma business ▶ ‘Wearable Pharma’: Going beyond insulin for smart wearable disease management EOFlow (KOSDAQ: 294090) (EOFlow or the Company), a provider of smart wearable drug delivery solutions, today announced that it will establish a pharmaceutical subsidiary ‘Pharmeo Inc.’ in Korea to secure new growth engine. EOFlow announced that it plans to establish a wholly owned subsidiary...Jul. 09. 2021
Healthcare Innovation Park #H2202 Dolma-ro 172 Bundang-gu Seongnam-si Gyeonggi-do Republic of Korea
T (+82) 031-738-0200
F (+82) 031-738-0208
COPYRIGHT ⓒ 2017 EOFLOW CO., LTD. All Rights Reserved.
